PCML
DYN icon

Pavaki Capital Management LLC’s Dyne Therapeutics DYN Stock Holding History

Pavaki Capital Management LLC’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$444K Hold
20,000
– – 0.15% 97
2026
Q1 		$363K Buy
+20,000
New +$345K 0.15% 98

Other funds holding DYN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Pavaki Capital Management LLC's DYN Position: Q2 2026 in Review

Pavaki Capital Management LLC held its Dyne Therapeutics (DYN) position steady in Q2 2026 at 20,000 shares worth $444K. The position accounts for 0.15% of the portfolio, ranked #97.

Pavaki Capital Management LLC first reported a position in DYN in Q1 2026 and has held it in 2 quarters since. 76 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Pavaki Capital Management LLC held 20,000 shares of Dyne Therapeutics worth $444K as of Q2 2026.
  • Pavaki Capital Management LLC left its Dyne Therapeutics share count unchanged in Q2 2026.
  • Dyne Therapeutics made up 0.15% of Pavaki Capital Management LLC's portfolio in Q2 2026, its #97 holding.
  • Pavaki Capital Management LLC first reported a position in Dyne Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 76 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Pavaki Capital Management LLC's 13F filing for Q2 2026, filed 7 Aug 2026.